https://prabadinews.com/
  • October 7, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

FDA Approves Emapalumab-Lzsg as First-Ever Treatment for Macrophage Activation Syndrome in Still Disease

FDA Approves Emapalumab-Lzsg as First-Ever Treatment for Macrophage Activation Syndrome in Still Disease

The FDA approves emapalumab-lzsg as the first treatment for macrophage activation syndrome in Still disease, offering a new treatment approach for patients with the rare condition.

administrator

Related Articles